Skip to Main Content

Alain P. Algazi


Medical oncologist
Immunologist, father and rather slow endurance athlete

Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.

In research, Algazi conducts clinical trials – studies that evaluate new therapies for head and neck cancers with an emphasis on approaches to improving the chances of long term remission in patients with incurable cancer using immunotherapy. He has also served the national study chair for clinical trials that give patients access to new medications and that provide new approaches of administering existing medications to improve their efficacy.

Algazi earned his medical degree from the David Geffen School of Medicine at UCLA and completed a residency in internal medicine at Ronald Reagan UCLA Medical Center. He completed a fellowship in hematology-oncology at UCSF.

Algazi is a member of the American Society of Clinical Oncology, Society for Immunotherapy for Cancer and American Association for Cancer Research.

To reach Dr. Alain Algazi, please contact the head and neck medical oncology practice at (415) 353-9900.

  • Education

    UCLA School of Medicine, 2004

  • Residencies

    UCLA Medical Center, Internal Medicine, 2007

  • Fellowships

    UCSF, Hematology-Oncology, 2010

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

There is a cure for every cancer. Our job is to find it.

Where I see patients (1)

    My reviews


    Overall Experience
    194 Ratings
    Explained things in a way that was easy to understand
    193 Ratings
    Did the doctor pay attention to your concerns
    193 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    186 Ratings
    Knew the important information about your medical history
    193 Ratings
    The provider showed respect for what you had to say
    192 Ratings
    The provider spent enough time with me
    191 Ratings
    Decorative Caduceus

    Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients Wit...

    For patients who do not have a tumor recurrence or death, DFS will be censored on the date of last disease assessment.


    Decorative Caduceus

    A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or M...

    Treatment emergent and treatment related adverse events (assessed by CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation, deaths


    Decorative Caduceus

    Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants...

    The occurrence of the following toxicities, if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration: Grade 4 nonhematologic toxicity (not laboratory) Grade 4 hematologic ...


    Decorative Caduceus

    A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

    Measured using RECIST 1.1


    Decorative Caduceus

    Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

    Safety and tolerability of NKTR-255 in combination with cetuximab as evaluated by dose limiting toxicities, incidence of drug-related Adverse Events (AEs), SAEs, and AEs leading to discontinuation, deaths, and clinical laboratory ...


    Decorative Caduceus

    Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

    Intratumoral CD3+ T-cells will be identified by immunohistochemistry in pre- and post-treatment tumor specimens. The analysis population for the primary outcome will be all patients who received at least 2 weeks of neoadjuvant the...


    Decorative Caduceus

    Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma ...

    TEAE's are defined as Adverse Events (AEs) with onset after date-time of first dose, or medical conditions present prior to the start of IMP but increased in severity or relationship after date-time of first dose of IMP.